Regeneron To Acquire Decibel Therapeutics At A Price Of $4/Share, Strengthening Gene Therapy And Hearing Loss Programs; Total Equity Value Of Up To ~$213M If The CVR Milestones Are Achieved
Portfolio Pulse from Happy Mohamed
Regeneron Pharmaceuticals (REGN) has announced a definitive agreement to acquire Decibel Therapeutics (DBTX) at $4 per share, with a total equity value of up to $213 million if certain milestones are achieved. The acquisition will strengthen Regeneron's gene therapy and hearing loss programs. Decibel's lead investigational gene therapy, DB-OTO, is currently in its first clinical trial. The transaction is expected to close in Q3 2023.
August 09, 2023 | 11:35 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Decibel Therapeutics is being acquired by Regeneron Pharmaceuticals at $4 per share.
The acquisition by Regeneron Pharmaceuticals could potentially increase the value of Decibel Therapeutics' stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Regeneron's acquisition of Decibel Therapeutics could strengthen its gene therapy and hearing loss programs.
The acquisition of Decibel Therapeutics could potentially strengthen Regeneron's position in the gene therapy and hearing loss market, which could positively impact its stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100